H.A'

0300

HA

attachment

DOCKET NO.: PHRM-0303 **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Mark E. Gurney et al.

Serial No.: 09/767,088 **Group Art Unit: Not Yet Assigned**

Filing Date: January 22, 2001 **Examiner: Not Yet Assigned**

For: TRANSGENIC MOUSE MODEL OF HUMAN NEURODEGENERATIVE DISEASE

DATE OF DEPOSIT: April 30 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

TYPED NAME: Robin S. Quartin
REGISTRATION NO.: 45,028

Assistant Commissioner for Patents
Washington DC 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:

☐ Certification in Accordance with §1.97(e) is attached; or

☐ The fee of **$180.00** as set forth in §1.17(p) is attached.

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with §1.97(e) is attached; or

☐ The fee of **$180.00** as set forth in §1.17(p) is attached.

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of **$180.00** as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references **[list as appropriate]**, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were

previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§120 have been made in the instant application:

☐ Copies of references **[list as appropriate]** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: April 30, 2001

Robin S. Quartin
Registration No. **45,028**

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

#4

Form PTO-1449 Modified	Docket No. **PHRM-0303**	Serial No. **09/767,088**
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant **Mark E. Gurney et al.**	
U.S. Department of Commerce Patent and Trademark Office	Filing Date **January 22, 2001**	Group **Not Yet Assigned**

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Arawaka, S. et al., "The tau mutation (val337met) disrupts cytoskeletal networks of microtubules", Neuroreport, **(1999)** 10:993-997
	AB	Brion, J.P. et al., "Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease", Am. J. Pathol., **(1999)**, 154:255-270
	AC	Brownlees, J. et al., "Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3β transgenes", Neuroreport, **(1997)**, 8:3251-3255
	AD	Clark, L.N., et al., "Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17", Proc. Natl. Acad. Sci. USA, **(1998)**, 95: 13103-13107
	AE	Dayanandan, R. et al., "Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation", FEBS Lett., **(1999)**, 446: 228-232
	AF	Dumanchin, C., et al., "Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism", Hum. Mol. Genet., **(1998)**, 7:1825-1829
	AG	Games, D. et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein", Nature, **(1995)**, 373:523-527
	AH	Goedert, M. et al., "Tau mutations cause frontotemporal dementias", Neuron, **(1998)**, 21:955-958
	AI	Goedert, M. et al., "Filamentous nerve cell inclusions in neurodegenerative diseases", Curr. Opin. Nuerobiol., **(1998)**, 8:619-632
	AJ	Götz, J., et al., "Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform", EMBO J., **(1995)**, 14:1304-1313
	AK	Gurney, M.E. et al., "Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis", Ann. Neurol., **(1996)**, 39:147-157
	AL	Gurney, M.E. et al., "Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation", Science, **(1994)**, 264:1772-1775

EXAMINER	**DATE CONSIDERED**

Form PTO-1449 Modified	Docket No. PHRM-0303	Serial No. 09/767,088
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant **Mark E. Gurney et al.**	
U.S. Department of Commerce Patent and Trademark Office	Filing Date **January 22, 2001**	Group **Not Yet Assigned**

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Hasegawa, M. et al., "Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly", FEBS Lett., **(1998)**, 437:207-210
	AN	Hasegawa, M., et al., "FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10", FEBS Lett., **1999**, 443:93-96
	AO	Hong, M. et al., "Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17", Science, **(1998)**, 282:1914-1917
	AP	Hutton, M. et al., "Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17", Nature, **(1998)**, 393:702-705
	AQ	Hsiao, K.K., "From prion diseases to Alzheimer's disease", J. Neural. Transm. Suppl., **(1997)**, 49:135-144
	AR	Iijima, M. et al., "A distinct familial presenile dementia with a novel missense mutation in the tau gene", Neuroreport, **(1999)**, 10:497-501
	AS	James, N.D. et al., "Neurodegenerative changes including altered tau phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase Mos", Neurobiol. Aging, **(1996)**, 17:235-241
	AT	Moechars, D. et al., "Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain", Biol. Chem., **(1999)**, 274:6483-6492
	AU	Nacharaju, P. et al., "Accelerated filament formation from tau protein with specific FTDP-17 missense mutations", FEBS Lett., **(1999)**, 447:195-199
	AV	Poorkaj, P. et al., "Tau is a candidate gene for chromosome 17 frontotemporal dementia", Ann. Neurol., **(1998)**, 43:815-825
	AW	Rizzu, P. et al., "High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands", Am. J. Hum. Genet., **(1999)**, 64:414-421
	AX	Spillantini, M.G. et al., "Comparison of the neurofibrillary pathology in Alzheimer's disease and familial presenile dementia with tangles", Acta Neuropathol., **(1996)**, 92:42-48

EXAMINER	**DATE CONSIDERED**

Form PTO-1449 Modified	Docket No. **PHRM-0303**	Serial No. **09/767,088**
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant **Mark E. Gurney et al.**	
U.S. Department of Commerce Patent and Trademark Office	Filing Date **January 22, 2001**	Group **Not Yet Assigned**

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AY	Spillantini, M.G. et al., "Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments", Proc. Natl. Acad. Sci. USA, **(1997)**, 94:4113-4118
	AZ	Spillantini, M.G. et al., "Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau", Am. J. Pathol., **(1998)**, 153:1359-1363
	BA	Spillantini, M.G. et al., "Mutation in the tau gene in familial multiple system tauopathy with presenile dementia", Proc. Natl. Acad. Sci. USA, **(1998)**, 95:7737-7741
	BB	Spillantini M.G. et al., "Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies", Brain Pathol., **(1998)**, 8:387-402
	BC	Spillantini, M.G. et al., "Tau protein pathology in neurodegenerative diseases", Trends Neurosci., **(1998)**, 21:428-433
	BD	Sturchler-Pierrat, C. et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology", Proc. Natl. Acad. Sci. USA, **(1997)**, 94:13287-13292
	BE	Tolnay, M. et al., "Tau protein pathology in Alzheimer's disease and related disorders", Neuropathol. Appl. Neurobiol., **(1999)**, 3:171-187
	BF	Wong, P.C. et al., "An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria", Neuron, **(1995)**, 14:1105-1116
	BG	Zehr, C. et al., "Production and characterization of tau transgenic mice", Soc. Neurosci., **(1999)**, 25:(A)447.1

EXAMINER	**DATE CONSIDERED**